Published in Silence on February 01, 2010
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther (2012) 1.14
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv (2013) 1.09
A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One (2011) 1.08
Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther (2012) 1.04
A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals (Basel) (2013) 0.99
Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol (2011) 0.96
A general RNA motif for cellular transfection. Mol Ther (2012) 0.94
Oligonucleotide conjugates for therapeutic applications. Ther Deliv (2013) 0.89
Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res (2013) 0.89
Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther (2012) 0.88
Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs (2012) 0.87
Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) (2013) 0.86
Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis (2012) 0.86
Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells. J RNAi Gene Silencing (2014) 0.86
Nucleic acids in human glioma treatment: innovative approaches and recent results. J Signal Transduct (2012) 0.83
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther (2013) 0.80
Aptamers as a novel tool for diagnostics and therapy. Invest New Drugs (2015) 0.80
RNAi-mediated knockdown of INHBB increases apoptosis and inhibits steroidogenesis in mouse granulosa cells. J Reprod Dev (2015) 0.80
Aptamers as both drugs and drug-carriers. Biomed Res Int (2014) 0.79
EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics (2015) 0.79
Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Mol Ther Nucleic Acids (2016) 0.79
Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy. RNA Biol (2015) 0.77
EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer. PLoS One (2015) 0.77
Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA. Pharmaceuticals (Basel) (2011) 0.77
Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo. Int J Nanomedicine (2014) 0.77
Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting. Nucleic Acid Ther (2011) 0.76
Aptamer technology for tracking cells' status & function. Mol Cell Ther (2014) 0.76
Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. PLoS One (2015) 0.76
Design and evaluation of thioalkylated mannose-modified dendrimer (G3)/α-cyclodextrin conjugates as antigen-presenting cell-selective siRNA carriers. AAPS J (2014) 0.75
Coupling Aptamers to Short Interfering RNAs as Therapeutics. Pharmaceuticals (Basel) (2011) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 20.32
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature (1990) 5.02
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature (1988) 4.15
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 3.27
Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell (1998) 3.21
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev (2007) 2.90
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
Tumor targeting by an aptamer. J Nucl Med (2006) 2.68
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 2.68
RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther (2006) 2.59
Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res (2010) 2.48
Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res (2008) 2.44
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
HIV-1 attachment: another look. Trends Microbiol (1999) 2.23
Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res (2006) 2.23
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A (2004) 2.21
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett (2004) 2.13
The chemical biology of aptamers. Angew Chem Int Ed Engl (2009) 2.09
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci (1993) 1.99
Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther (2005) 1.81
Cell-specific internalization study of an aptamer from whole cell selection. Chemistry (2008) 1.81
Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem (2001) 1.81
Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther (2006) 1.79
Differential endocytosis of CD4 in lymphocytic and nonlymphocytic cells. J Exp Med (1991) 1.78
Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem (2007) 1.69
RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol (2005) 1.68
RNA aptamers as effective protein antagonists in a multicellular organism. Proc Natl Acad Sci U S A (1999) 1.62
Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther (2008) 1.59
Therapeutic applications of DNA and RNA aptamers. Oligonucleotides (2009) 1.59
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl (2009) 1.50
Construction of phi29 DNA-packaging RNA monomers, dimers, and trimers with variable sizes and shapes as potential parts for nanodevices. J Nanosci Nanotechnol (2003) 1.50
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA (2007) 1.46
Engineering mucosal RNA interference in vivo. Mol Ther (2006) 1.43
Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc (2009) 1.43
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem (2007) 1.42
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett (2004) 1.41
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol (2001) 1.39
Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J Virol (2003) 1.37
Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res (2005) 1.36
Computer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motor. J Biol Chem (2002) 1.36
Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem (2003) 1.35
Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew Chem Int Ed Engl (2008) 1.35
Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther (2007) 1.34
Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest (2000) 1.33
Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol (2008) 1.32
Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. Nucleic Acids Res (2002) 1.29
Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res (2003) 1.27
Automated RNA selection. Biotechnol Prog (1999) 1.27
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem (2004) 1.24
Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets (2008) 1.24
Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res (2008) 1.23
Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci U S A (2008) 1.21
Alternative drug formulations of docetaxel: a review. Anticancer Drugs (2007) 1.18
Development of a nonviral gene delivery vehicle for systemic application. Bioconjug Chem (2002) 1.18
CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci (2008) 1.17
Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. Nucleic Acids Res (2005) 1.17
Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol (2005) 1.15
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (2005) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Functional siRNA expression from transfected PCR products. RNA (2002) 1.42
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A (2009) 1.38
HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res (2005) 1.37
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR. Nucleic Acids Res (2009) 1.35
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34
A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther (2007) 1.34
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther (2003) 1.29
RNAi and the P-body connection. Nat Cell Biol (2005) 1.29
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res (2008) 1.25
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19
A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Expressing short hairpin RNAs in vivo. Nat Methods (2006) 1.14
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res (2010) 1.11
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther (2003) 1.10
Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther (2007) 1.08
Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07
Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07
Control of HIV-1 replication by RNA interference. Virus Res (2004) 1.05
Amplification of RNAi--targeting HLA mRNAs. Mol Ther (2005) 1.05
Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev (2003) 1.04
Uncoupling of RNAi from active translation in mammalian cells. RNA (2004) 1.04
Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One (2012) 1.04
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol (2005) 1.03
Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res (2007) 1.02
The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem (2009) 0.99
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One (2010) 0.99
Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B). J Mol Cell Cardiol (2004) 0.98
Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. Anal Chem (2012) 0.98
Epigenetics and microRNAs. Pediatr Res (2007) 0.98
Progress in RNAi-based antiviral therapeutics. Methods Mol Biol (2011) 0.98
Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum Gene Ther (2006) 0.98
Sensing the danger in RNA. Nat Med (2005) 0.97
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods (2011) 0.97
Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol (2011) 0.94
Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. Mol Ther (2004) 0.93
Principles of Dicer substrate (D-siRNA) design and function. Methods Mol Biol (2008) 0.93
Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
Recent applications of RNAi in mammalian systems. Curr Pharm Biotechnol (2004) 0.92
Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. Methods Enzymol (2005) 0.91
Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses (2013) 0.91
Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. Mol Ther (2008) 0.91
MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol Sci (2011) 0.90